Contrast medium for pancreatic cancer MR imaging

A contrast agent, pancreatic cancer technology, applied in nanotechnology for sensing, preparations for in vivo experiments, active ingredients of heavy metals, etc., can solve the problems of distant metastasis and lack of effective treatment for PDAC

Inactive Publication Date: 2020-02-28
SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV +3
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This may be due to severe local invasion or distant metastasis at the time of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Contrast medium for pancreatic cancer MR imaging
  • Contrast medium for pancreatic cancer MR imaging
  • Contrast medium for pancreatic cancer MR imaging

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Embodiment 1 (IONPs of modifying three kinds of single-chain antibodies)

[0033] This example provides a contrast agent (IONPs-PEG-MCC triplescAbs) for MR imaging of pancreatic cancer, the contrast agent includes: PEGylated iron oxide nanoparticles, and three types of single-chain antibody surface modification; three All the single-chain antibodies are coupled with the pegylated iron oxide nanoparticles; the three single-chain antibodies are anti-MUC4 single-chain antibody, anti-CEACAM6 single-chain antibody, and anti-CD44v6 single-chain antibody.

[0034] 1. Synthesis of three kinds of single-chain antibodies (anti-MUC4 single-chain antibody, anti-CEACAM6 single-chain antibody, anti-CD44v6 single-chain antibody)

[0035] Use mouse anti-human MUC4 and mouse anti-human CEACAM6 monoclonal antibodies to obtain scAbMUC4 and scAbCEACAM6 by selectively cutting the disulfide bond of the heavy chain hinge region in the complete monoclonal molecule.

[0036] Add 100 μL of anti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a contrast medium for pancreatic cancer MR imaging. The contrast medium comprises pegylated iron oxide nanoparticles and single-chain antibodies for surface moficiation. The single-chain antibodies are coupled with the pegylated iron oxide nanoparticles and selected from an anti-MUC4 single-chain antibody, an anti-CEACAM6 single-chain antibody and an anti-CD44v6 single-chainantibody. Single-chain antibody modified INOPs (iron oxide nanoparticles) can serve as an MR imaging T2 sequence contrast medium. The INOPs modified with three types of single-chain antibodies are superior to the INOPs modified with two types of single-chain antibodies in negative developing effect and lasting time; The INOPs modified with two types of single-chain antibodies are superior to theINOPs modified with one type of single-chain antibody in negative developing effect and lasting time. The single-chain antibody modified INOPs can be gathered in a tumor area and less retained in spleen, and hepatic and renal toxicity after radiography is avoided. A IONPs complex modified with the three types of single-chain antibodies can be used as a novel sensitive and efficient MR imaging T2 contrast medium, has an anti-pancreatic-cancer effect and is a pancreatic cancer diagnosis and treatment integrated difunctional nanomaterial.

Description

technical field [0001] The invention relates to a contrast agent for MR imaging of pancreatic cancer. Background technique [0002] Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest human cancers, with a 5-year relative survival rate of approximately 6%, and the seventh leading cause of cancer death. This may be due to severe local invasion or distant metastasis at the time of diagnosis, and currently clinically discovered PDAC lacks effective treatment. So far, one of the important research directions to improve the prognosis of PDAC is the precise diagnosis of pancreatic cancer. MRI, especially enhanced MR contrast imaging, is an important method for the detection and diagnosis of pancreatic lesions. In MR enhanced contrast imaging, the development of sensitive and efficient The contrast agent is one of the important directions in the research of MR-enhanced imaging. [0003] Magnetic iron oxide nanoparticles (IONPs) have been intensively researched and dev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K49/12A61K49/16A61K49/18A61K47/60A61K47/68A61K33/26A61P35/00B82Y5/00B82Y15/00
CPCA61K33/26A61K49/126A61K49/16A61K49/186A61K49/1875A61K47/60A61K47/6803A61P35/00B82Y5/00B82Y15/00
Inventor 陈茵婷黄开红邹金茂练国达陈少杰陈尚祥李雅晴李宣娜谭莹
Owner SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap